Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma

Abramson Cancer Center at Penn Medicine0 sitesNovember 2013

ConditionsMelanoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Melanoma
Sponsor: Abramson Cancer Center at Penn Medicine
Primary Endpoint: Number of changes in CTC level from pre- to post-treatment
Status: Withdrawn
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This research trial studies the levels of a type of biomarker, circulating tumor cells (CTCs), in the blood of patients with stage I-IV melanoma. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Studying samples of blood in the laboratory obtained before and after treatment from patients with melanoma may help doctors learn more about changes that occur in CTC levels and whether they may predict how well patients will respond to therapy.

Registry

clinicaltrials.gov

Start Date

November 2013

End Date

December 2013

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Abramson Cancer Center at Penn Medicine

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects must have signed tissue collection consent as described in protocol IRB# 703001,UPCC# 08607, PI: Giorgos Karakousis, MD
•Subjects must be competent to consent for themselves.
•Subjectsmust be adult (18 years or older).
•Subjects must be initiating a new therapy for melanoma (so a pretreatment CTC count can be obtained).